Complement-Mediated Acute Effects of Liposome-Encapsulated Hemoglobin

References

• Anand N., Paterson W. G. Role of nitric oxide in esophageal peristalsis. Am. J Physiol. 1994; 266: G123–G131
   Google Scholar
• Zuck T. F., Riess J. G. Current status of injectable oxygen carriers. Crit. Rev. Clin. Lab. Sci 1994; 31: 295–324
   PubMed Web of Science ®Google Scholar
• Winslow R. M. Artificial Red Cells: Materials, Performances and Clinical Study as Blood Substitutes, E Tsuchida. John Wiley & Sons Ltd., New York 1995; 117–130
   Google Scholar
• Murray J. A., Ledlow A., Launspach J, Evans D, Loveday M., Conklind J. L. The effects of recombinant human hemoglobin on esophageal motor function in humans. Gastroenterology 1995; 109: 1241–1248
   PubMed Web of Science ®Google Scholar
• Rudolph AS, Sulpizio A., Hieble P., MacDonald V., Chavez M., Feurstein G. Liposome encapsulation attenuates hemoglobin-induced vasoconstriction in rabbit arterial segments. J. Appl. Physiol. 1997; 82: 1826–1835
   PubMed Web of Science ®Google Scholar
• Rabinovici R, Rudolph A. S., Feuerstein G. Characterization of hemodynamic, hematologic and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ. Shock 1989; 29: 115–132
   PubMedGoogle Scholar
• Rudolph A. S. Blood Substitutes. Physiological Basis of Efficacy, R.M. Winslow, K.D. Vandegriff, M Intaglietta. Birkhauser, Boston 1995; 98–104
   Google Scholar
• Tsuchida E., Takeoka S. Artificial Red Cells, E. Tsuchida. John Wiley & Sons Ltd, New York 1995; 35–64
   Google Scholar
• Szebeni J, Wassef N. M., Rudolph A. S., Alving C. R. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim Biophys. Acta 1996; 12(85)127–130
   Google Scholar
• Rabinovici R, Phillips W. T., Feuerstein G., Rudolph A. S. Red Blood Cell Substitutes: Fundamental Principles and Clinical Applications, R Rabinovici, G. Feuerstein, AS Rudolph. Marcel Dekker, New York 1998; 263–287
   Google Scholar
• Hunt C. A., Burnette R. R., MacGregor R. D., Strubbe A, Lau D. T., Taylor N., Kawada H. Synthesis and evaluation of a prototypal artificial red cell. Science 1985; 230: 1165–1168
   PubMed Web of Science ®Google Scholar
• Rudolph A. S., Klipper R. W., Goins B., Phillips W. T. In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc. Natl. Acad. Sci. USA 1991; 88: 10976–80
   PubMed Web of Science ®Google Scholar
• Phillips W.T, Rudolph A. S., Goins B., Klipper R. Biodistribution studies of liposome encapsulated hemoglobin (LEH) studied with a newly developed 99m-technetium liposome label. Biomat. Artif. Cells Immobil. Biotechnol 1992; 20: 757–60
   PubMed Web of Science ®Google Scholar
• Rudolph A. S., Sulpizio T., Kwasiborski V., Cliff R. O., Rabinovici R., Feurstein G. Infusion of liposome-encapsulated hemoglobin in normovolemic primates. Artif Cells, Blood Subst. Immob. Biotechnol. 1996; 24: 415
   Google Scholar
• Takaori M., Fukui A. Treatment of massive hemorrhage with liposome encapsulated human hemoglobin (NRC) and hydroxyethyl starch (HES) in beagles. Artif. Cells Blood Substit. Immobil. Biotechnol. 1996; 24: 643–653.
   PubMed Web of Science ®Google Scholar
• Usuba A., Motoki R. Effect of liposome encapsulated hemoglobin “neo red cells” on severe hemorrhagic shock. Artif. Cells Blood Substit. Immobil. Biotechnol. 1997; 25: 379–392
   Google Scholar
• Goins B, Phillips W. T., Klipper R., Rudolph A. S. Role of complement in rats injected with liposome-encapsulated hemoglobin. J. Surg. Res. 1997; 68: 99–105
   PubMedGoogle Scholar
• Rollwagen F. M., Gafney W. C., Pacheco N. D., Davis T. A., Hickey T. M., Nielsen T. B., Rudolph A. S. Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels. Exp. Hematol. 1996; 24: 429–36
   PubMed Web of Science ®Google Scholar
• Djordjevich L., Miller I. F. Synthetic erythrocytes from lipid-encapsulated hemoglobin. Exp. Hematol. 1980; 8: 584–592
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Miyauchi Y, Suzuki K., Takayashi A. Effects of the neo red cell on the blood coagulation system and the complement system. Jap. J. Artif. Organs 1994; 20: 620–625
   Google Scholar
• Rabinovici R., Rudolph A. S., Feuerstein G. Improved biological properties of synthetic distearoyl phosphatidylcholine-based liposome in the conscious rat. Circ. Shock 1990; 30: 207–219
   PubMedGoogle Scholar
• Rabinovici R., Rudolph A. S., Yue T.-L., Feuerstein G. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ. Shock. 1990; 31: 431–445
   PubMedGoogle Scholar
• Rabinovici R., Rudolph A. S., Ligler F. S., Smith E.F., III, Feuerstein G. Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. Circ. Shock. 1992; 37: 124–33
   PubMedGoogle Scholar
• Phillips W. T., Klipper R., Fresne D., Rudolph A. S., Javors M., Goins B. Platelet reactivity with liposome-encapsulated hemoglobin in the rat. Exp. Hematol. 1997; 25: 1347–1356
   PubMedGoogle Scholar
• Wassef N. M., Johnson S. H., Graeber G. M., Swartz G. M., Schultz C. L., Hailey J. R., Johnson A. J., Taylor D. G., Ridgway R. L., Alving C. R. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J. Immunol. 1989; 143: 2990–2995
   PubMed Web of Science ®Google Scholar
• Szebeni J., Fontana J. L., Mongan P. D., Stahl G. L., Wassef N. M., Bunger R., Alving C. R. Hemodynamic changes in pigs induced by liposomes and liposome-encapsulated hemoglobin: The role of complement. 1998, Manuscript submitted.
   Google Scholar
• Szebeni J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carr. Syst. 1998; 15: 57–89
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wassef N. M., Spielberg H., Rudolph A. S., Alving C. R. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem. Biophys. Res. Comm. 1994; 205: 255–263
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wassef N. M., Rudolph AS., Alving C. R. Complement activation by liposome-encapsulated hemoglobin: the role of natural in vitro:the role of endotoxin contamination. Artif. Cells Blood Subs, and Immob. Biotechnol. 1995; 23: 355–363
   PubMed Web of Science ®Google Scholar
• Szebeni J., Spielberg H., Cliff R. O., Wassef N. M., Rudolph A. S., Alving C. R. Complement activation and thromboxane A2 secretion in rats following administration of liposome-encapsulated hemoglobin: Inhibition by soluble complement receptor type 1. Art. Cells, Blood Subs. Immob. Biotechnol. 1997; 25: 379–392
   PubMedGoogle Scholar
• Szebeni J, Wassef NM, Hartman K R, Rudolph A S, Alving C R. Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 1997; 37: 150–159
   PubMed Web of Science ®Google Scholar
• Hugh T E. Structure and function of anaphylatoxins. Spring. Semin. Immunopathol. 1984; 7: 193–219
   PubMedGoogle Scholar
• Marceau F, Lundberg C, Hugli T E. Effects of anaphylatoxins on circulation. Immunopharmacol. 1987; 14: 67–84
   PubMed Web of Science ®Google Scholar
• Szebeni J, Hauser H, Eskelson CD, Watson R R, Winterhalter H K. Interaction of hemoglobin derivatives with liposomes. Membrane cholesterol protects against the changes of hemoglobin. Biochemistry 1988; 27: 6425–6434
   Google Scholar
• Rabinovici R, Rudolph A S, Ligler F S, Yue T-L., Feuerstein G. Liposome-encapsulated hemoglobin: an oxygen-carrying fluid. Circ. Shock 1990; 32: 1–17
   PubMedGoogle Scholar
• Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991; 146: 4234–4241
   PubMed Web of Science ®Google Scholar
• Moore FDJ., Austen KF., Fearon DT. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J. Immunol. 1982; 128: 1302–1306
   PubMed Web of Science ®Google Scholar
• Fries LF, Gaither T A, Hammer C H, Frank M. M C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J. Exp. Med. 1984; 160: 1640–1655
   PubMedGoogle Scholar
• Stahl G L, Amsterdam E A, Symons J D, Longhurst J C. Role of thromboxane A2 in cardiovascular response to intracoronary C5a. Circ. Res. 1990; 66: 1103–1111
   PubMedGoogle Scholar
• Stahl G., Morse D. S., Martin S. L. Eicosanoid production from porcine neutrophils and platelets: differential production with various agonists. Am. J. Physiol. 1997; 272: C1821–C1828
   Google Scholar
• Stahl GL, Reenstra W R, Frendl G. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of terminal membrane attack complex. Circ. Res. 1995; 76: 575–583
   Google Scholar
• Salama A, Hugo F, Heinrich D, Hoge R, Muller R, Kiefel V, Mueller-Eckhardt C, Bhakdi S. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N. Eng. J. Med 1988; 318: 408–414
   PubMed Web of Science ®Google Scholar
• del Basso P, Argiolas L. Cardiopulmonary effects of endothelin-1 in the guinea pig: role of thromboxane A2. J. Cardiovasc. Pharmacol. 1995; 26: S120–2
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Burman H P, O'Donnell C P, Cahill P A, Robotham J L. Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock. Am. J. Physiol. 1997; 272H: 1239–1249
   Google Scholar
• Hammerschmidt D E, Hudson L D, Weaver L J, Craddock P R, Jacob H S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Lancet May 3, 1980; 947–949
   PubMedGoogle Scholar
• Hammerschmidt D E. Complement in Health and Disease, K Whaley. MTP Press, Lancester/Boston 1986; 267–287
   Google Scholar
• Levine S J, Walsh T J, Martinez A, Eichacker P Q, Lopez-Berstein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Annals Int. Med. 1991; 114: 664–666
   PubMed Web of Science ®Google Scholar
• Laing R B. S, Milne L J. R, Leen C L. S, Malcolm G P, Steers A J. W. Anaphylactic reactions to liposomal amphotericin. Lancet 1994; 344: 682
   PubMed Web of Science ®Google Scholar
• Ringdén O, Andstrom E, Remberger M, Svahn B M, Tollemar J. Allergic reactions and other rare side effects of liposomal amphotericin. Lancet 1994; 344: 1156–1157
   PubMed Web of Science ®Google Scholar
• de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10(2.)S93–S96, Suppl.
   Google Scholar
• Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia F M, Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995; 13: 1777–85
   PubMed Web of Science ®Google Scholar
• Dezube B. Doxil Clinical Series. Sequus Pharmaceuticals Inc., Menlo Park, CA 1996; Vol. 1: No. 2.
   Google Scholar
• Alberts D S, Garcia D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54: 30–45, Suppl. 4
   Google Scholar
• Weisman H F, Bartow T, Leppo M K, Marsh H C. J, Carson G R, Concino M F, Boyle M P, Roux K H, Weisfeldt M L, Fearon D T. Soluble complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146–151
   PubMed Web of Science ®Google Scholar
• Cheung A K, Parker C J, Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int. 1994; 46: 1680–7
   PubMed Web of Science ®Google Scholar
• Smith E, de Griswold D E, Egan J W, Hillegass LM, Smith R A, Hibbs M J, Gagnon R C. Reduction of myocardial reperrusion injury with human soluble complement receptor type 1 (BRL 55730). Eur. J. Pharmacol. 1993; 236: 477–81
   PubMedGoogle Scholar
• Gillinov A M, DeValeria P A, Winkelstein J A, Wilson I, Curtis W E, Shaw D, Yeh C G, Rudolph A R, Baumgartner W A, Herskowitz A. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann. Thorac. Surg. 1993; 55: 619–24
   PubMed Web of Science ®Google Scholar
• Dickneite G. Weir's Handbook of Experimental Immunology, LA Herzenberg, L A. Herzenberg, C Blackwell. Blackwell Science, Cambridge 1996; 218.1–218.7
   Google Scholar
• Cable D G, Hisamochi K, Schaff H V. Complement mediates attenuation of endothelium-dependent relaxations in canine coronary arteries after porcine serum exposure: a mechanism for vascular thrombosis in xenograft hyperacute rejection. Circulation 1997; 96: II–II5863, 9 Suppl
   Google Scholar
• Lennon P F, Collard C D, Morrissey M A, Stahl G L. Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences. Am. J. Physiol. 1996; 270: H1924–H1932
   Google Scholar
• Pierson RR., Parker R E. Thromboxane mediates pulmonary vasoconstriction and contributes to cytotoxicity in pig lungs perfused with fresh human blood. Transplant. Proa 1996; 28: 625
   PubMed Web of Science ®Google Scholar
• Rinder CS, Rinder H M, Smith BR, Fitch J C. K, Smith J M. J, Tracey B, Matis L A, Squinto S P, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Invest 1995; 96: 1564–1572
   PubMedGoogle Scholar
• Shibamoto T, Wang H G, Yamaguchi Y, Hayashi T, Saeki Y, Tanaka S, Koyama S. Effects of thromboxane A2 analogue on vascular resistance distribution and permeability in isolated blood-perfused dog lungs. Lung 1995; 173: 209–21
   PubMed Web of Science ®Google Scholar
• Thies SD, Corbin R S, Goff CD, Binns O A, Buchanan S A, Shockey KS, Frierson H F, JR., Young J S, Tribble C G, Kron I L. Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury. Ann. Thorac Surg. 1996; 61: 1453–7
   PubMed Web of Science ®Google Scholar